Institut Pasteur Launches ACT-CHIK to Advance Chikungunya Vaccine Development in Africa
Institut Pasteur has initiated a four-year research project named ACT-CHIK, aimed at advancing the development of a chikungunya vaccine in Africa. Funded by the Global Health EDCTP3 Joint Undertaking under the European Union’s Horizon Europe program, the project has received €15.3 million to support large-scale Phase Ib/III clinical trials in Rwanda, Kenya, Nigeria, and Senegal. The vaccine, MV-CHIK, is a measles-virus-based candidate originally developed at Institut Pasteur. The initiative seeks to address the growing burden of chikungunya, a mosquito-borne viral disease, by generating critical clinical data and preparing for regional vaccine manufacturing. The project also aims to transfer vaccine manufacturing technology to the Institut Pasteur de Dakar, Africa’s only WHO-prequalified vaccine manufacturer.